Latest Breaking News On - Immunos therapeutics - Page 1 : comparemela.com

ImmunOs Therapeutics Presents Details of Novel Bispecific Anti-Tumor Molecules at ESMO Immuno-Oncology Congress 2023

HLA/SIRPa bispecifics targeting LILRB1/2 plus CD47 checkpoint receptorDesigned to target myeloid, NK and T cells and to be precisely directed to t.

United statesMarroquin belaunzaranLudger wess ines regina buthSchroder adveqOncology congressMission biocapitalCompany contactZurich areaImmunos therapeuticsOsiris marroquin belaunzaranSteve coatsSamsara biocapitalLightspeed venture partnersPfizer venturesBiomed partnersLudger wess

ImmunOs Therapeutics Presents Overview of Phase 1a/b Trial of Lead Compound IOS-1002

Evaluation of IOS-1002, a LILRB1 (ILT2), LILRB2 (ILT4), KIR3DL1 targeting agent, as monotherapy and in combination with pembrolizumab in advanced solid tumorsTrial overview presented at ESMO Congress 2023 (Madrid, Spain)Dose

United statesSchroder adveqChristoph rennerLudger wess ines regina buthCompany contactMission biocapitalZurich areaImmunos therapeuticsSamsara biocapitalLightspeed venture partnersPfizer venturesBiomed partnersLudger wess

ImmunOs Therapeutics Announces Clinical Trial Collaboration with Merck & Co , Inc , Rahway,

- Evaluation of IOS-1002, a LILRB1 (ILT2), LILRB2 (ILT4), KIR3DL1 targeting agent, in combination with KEYTRUDA® (pembrolizumab) as part of ongoing Phase 1a/b trial in advanced solid tumors

United statesSchroder adveqSeanr smithChristoph rennerLudger wess ines regina buthMerck co incMission biocapitalMerck sharp dohmeZurich areaImmunos therapeuticsChief medical officerChief executive officerMerck sharpSamsara biocapitalLightspeed venture partnersPfizer ventures

ImmunOs Therapeutics Announces Appointment of Joseph Leveque, MD, to its Board of Directors

ImmunOs Therapeutics Announces Appointment of Joseph Leveque, MD, to its Board of Directors
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Santa clara universityUnited statesWharton schoolUniversity of texasLudger wess ines regina buthJoseph levequeSeanr smithEli lillyJoe levequeBristol myers squibbLos angelesSchroder adveqUniversity of californiaSinai medical centerMission biocapitalCompany contactimmunos therapeutics ag wagistrasse

ImmunOs Therapeutics Announces Appointment of Joseph

- Seasoned immuno-oncology executive brings significant medical and biopharma expertise Schlieren (Zurich Area), Switzerland, and Gaithersburg, MD,.

Santa clara universityUnited statesWharton schoolUniversity of texasLudger wess ines regina buthJoseph levequeSeanr smithEli lillyJoe levequeBristol myers squibbLos angelesSchroder adveqUniversity of californiaSinai medical centerCompany contactMission biocapital